Boundless Bio, Inc.
Cancer therapeutics targeting extrachromosomal DNA (ecDNA) in cancer cells
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2018
- Latest Form D
- $100M, Aug 2023
- Total capital
- $229M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $229M
- 3 Form D · last Aug 2023
- 38 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 35 pending · first 2023
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$100M
- Private capital raisedForm D · SEC · 2nd filing$106M
- Private capital raisedForm D · SEC · 1st filing$23.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Benjamin Sung Cravatt, Ph.D.DirectorNamed in SEC Form D filings
- Carolyn D. Ng, Ph.D.DirectorNamed in SEC Form D filings
- Chris D. Hassig, Ph.D.DirectorNamed in SEC Form D filings
- Christine D. Brennan, Ph.D.DirectorNamed in SEC Form D filings
- Fabio D. Pucci, Ph.D.DirectorNamed in SEC Form D filings
- Ho Sung Cho, Ph.D.DirectorNamed in SEC Form D filings
Show all 13 people
- Jakob D. Loven, Ph.D.DirectorNamed in SEC Form D filings
- Jason D. Christiansen, Ph.D.DirectorNamed in SEC Form D filings
- Jennifer D. LewDirectorNamed in SEC Form D filings
- Jonathan E. Lim, M.D.DirectorNamed in SEC Form D filings
- Kristina E. BurowDirectorNamed in SEC Form D filings
- Scott D. Moorefield, Ph.D.DirectorNamed in SEC Form D filings
- Zachary D. HornbyExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 40- PendingPyridine Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofUSPTOApplication 18867586
- PendingCyclic Sulfonamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofUSPTOApplication 19110333
- GrantedCheckpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofUSPTOUS 12,527,790
Show all 40 patent records
- Pyridine Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofMay 21, 2026 · Application 18867586Pending
- Cyclic Sulfonamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofMar 26, 2026 · Application 19110333Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofJan 20, 2026 · US 12,527,790Granted
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerMar 11, 2025 · US 12,246,017Granted
- Cyclic Sulfonamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofJan 2, 2025 · Application 18692503Pending
- Sulfamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofDec 26, 2024 · Application 18692505Pending
- Phenol Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofAug 29, 2024 · Application 18433734Pending
- WEE1 Inhibitors And Uses ThereofJul 11, 2024 · Application 18390368Pending
- Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofMay 16, 2024 · Application 18547794Pending
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerAug 31, 2023 · Application 18169797Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofJul 25, 2023 · US 11,707,462Granted
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerMay 9, 2023 · US 11,642,345Granted
- Computer-implemented Methods For Quantitation Of Features Of Interest In Whole-slide ImagingApr 20, 2023 · Application 17906206Pending
- Method Of Identifying Extrachromosomal Dna SignaturesApr 6, 2023 · Application 17907147Pending
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerJan 10, 2023 · US 11,547,711Granted
- Pyridine Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofApplication PCTUS2023067358Pending
- Checkpoint Kinase 1 (CHK1) Inhibitor Crystalline Form And Uses ThereofApplication 63493846Pending
- KIF22 Degraders And Uses ThereofApplication PCTUS2026015963Pending
- KIF22 Inhibitors And Uses ThereofApplication PCTUS2026015964Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors Combinations And Uses ThereofApplication 19133346Pending
- KIF22 Inhibitors And Uses ThereofApplication 63761446Pending
- KIF22 Degraders And Uses ThereofApplication 63761441Pending
- Checkpoint Kinase 1 (CHK1) Inhibitor Pharmaceutical CompositionApplication 63493847Pending
- Uses Of A Checkpoint Kinase 1 (CHK1) InhibitorApplication 63491198Pending
- WEE1 Inhibitors And Uses ThereofApplication 63476846Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofApplication 63385344Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors Combinations And Uses ThereofApplication 63385347Pending
- Pyridine Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofApplication 63385340Pending
- Sulfamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofApplication PCTUS2022043682Pending
- Cyclic Sulfonamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofApplication PCTUS2022043660Pending
- Cyclic Sulfonamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofApplication 63375495Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofApplication PCTUS2022031141Pending
- Pyridine Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofApplication 63345116Pending
- Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofApplication PCTUS2022018279Pending
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerApplication 63310968Pending
- Cyclic Sulfonamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofApplication 63245718Pending
- Sulfamide Ribonucleotide Reductase (rnr) Inhibitors And Uses ThereofApplication 63245720Pending
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerApplication PCTUS2021045556Pending
- Checkpoint Kinase 1 (CHK1) Inhibitors And Uses ThereofApplication 63193990Pending
- Replication Stress Pathway Agent Compositions And Methods For Treating CancerApplication 63168120Pending
Related companies, and why
- OcuTerra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Ratio Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NANOMEDTRIX LLCSimilar federal contract value in Biotech · null in contracts
- Treeline BiosciencesSimilar federal contract value in Biotech · null in contracts
- ESTRIGENIX THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .